MHRA approves Siiltibcy as a diagnostic aid for Mycobacterium tuberculosis infection, including disease

Public list of companies in the UK who have had their licence/registration to manufacture or wholesale medicines/ingredients revoked or suspended.

A batch of Depo-Medrone has been released to the market with an error. The vial over label incorrectly states that the total vial content is 40 mg in 1 mL, when the correct total vial content is 80mg in 2 mL (with a concentration of 40mg/ml of methylprednisolone acetate).

Patients implanted with affected devices should expect to be contacted directly for a follow-up assessment, if required.

How to apply for a clinical trial from 28 April 2026, including eligibility, phases, model IMPDs, costs and how to make changes to your application.

Clinical trial applications that need expert advice from a specialist group or committee.

As with any medicine, the MHRA will keep the safety and effectiveness of zapomeran under close review.